Neonatal Seizures – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Neonatal Seizures Market Outlook
Thelansis’s “Neonatal Seizures Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Neonatal Seizures treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Neonatal
Seizures Overview
Neonatal
Seizures represent the most distinctive frequent manifestations of neurological
dysfunction in the neonatal period. Neonatal seizures are clinically described
as abnormal, stereotyped and paroxysmal dysfunctions in the central nervous
system (CNS) occurring within the first 28 days after birth in full-term
infants or before 44 weeks of gestational age in preterm infants. It is a
relatively common occurrence in neonates with a heterogeneous etiology, and
most infants are acutely symptomatic. The etiologies are different in term and
preterm infants. Hypoxic-ischemic encephalopathy (HIE), stroke, cerebral
malformations and metabolic disorders are major causes of seizures in term
infants. Some significant causes in preterm infants are intraventricular
haemorrhage (IVH), periventricular leukomalacia (PVL) and infections. Neonatal
seizures are often the first clinical sign of underlying neurological
dysfunction, with the most common causes being hypoxic-ischemic encephalopathy
(HIE), perinatal stroke and intracranial haemorrhage. Due to the frequency of
these conditions and the relative excitability of the newborn brain, the
neonatal period, in particular the first week of life, is the most vulnerable
period for the development of seizures.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment